Revolution Medicines (RVMDW) Accumulated Depreciation (2019 - 2026)

Revolution Medicines' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 31.22% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $30.7 million (up 31.22% YoY), while the FY2025 annual figure was $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $30.7 million, up from $28.5 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $30.7 million in Q1 2026, with the low at $11.6 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $18.9 million (2024), against an average of $19.9 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation soared 35.59% in 2023, then rose 19.86% in 2024.
• Revolution Medicines' Accumulated Depreciation stood at $14.5 million in 2022, then rose by 22.12% to $17.7 million in 2023, then gained by 23.34% to $21.8 million in 2024, then surged by 30.66% to $28.5 million in 2025, then gained by 7.6% to $30.7 million in 2026.
• Business Quant data shows RVMDW's Accumulated Depreciation at $30.7 million in Q1 2026, $28.5 million in Q4 2025, and $27.0 million in Q3 2025.